Quick Answer
Avalo Therapeutics, Inc. reported Operating Income Loss of -$72.93 million for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -6.4% in Operating Income Loss from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$6.00 million | Q1 2015: -$2.48 million | Q2 2015: -$2.89 million | Q3 2015: -$1.96 million | Q1 2016: -$4.94 million | Q2 2016: -$3.49 million | Q3 2016: -$5.96 million | Q1 2017: -$1.90 million | Q2 2017: -$1.77 million | Q3 2017: $21.92 million | Q1 2018: -$3.75 million | Q2 2018: -$5.75 million | Q3 2018: -$24.31 million | Q1 2019: -$5.00 million | Q2 2019: -$2.55 million | Q3 2019: -$2.86 million | Q1 2020: -$31.41 million | Q2 2020: -$11.82 million | Q3 2020: -$13.28 million | Q1 2021: -$30.58 million | Q2 2021: -$17.13 million | Q3 2021: -$16.46 million | Q1 2022: -$20.85 million | Q2 2022: -$11.83 million | Q3 2022: $4.10 million | Q1 2023: -$8.79 million | Q2 2023: -$7.15 million | Q3 2023: -$3.75 million | Q1 2024: -$32.77 million | Q2 2024: -$9.58 million | Q3 2024: -$12.86 million | Q1 2025: -$14.67 million | Q2 2025: -$19.32 million | Q3 2025: -$19.20 million.
- Over the full 13 years of available data (2013 to 2025), Avalo Therapeutics, Inc.'s Operating Income Loss has declined by 463.8%.
- Historical annual values: Fiscal year 2025: -$72.93 million | Fiscal year 2024: -$68.51 million | Fiscal year 2023: -$27.35 million | Fiscal year 2022: -$37.44 million | Fiscal year 2021: -$82.13 million | Fiscal year 2020: -$72.84 million | Fiscal year 2019: -$16.14 million | Fiscal year 2018: -$35.38 million | Fiscal year 2017: $13.89 million | Fiscal year 2016: -$16.08 million | Fiscal year 2015: -$11.01 million | Fiscal year 2014: -$17.12 million | Fiscal year 2013: -$12.93 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: